Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

Leuk Lymphoma. 2023 Mar;64(3):738-741. doi: 10.1080/10428194.2022.2164194. Epub 2023 Jan 15.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CREB-Binding Protein / genetics
  • E1A-Associated p300 Protein / genetics
  • Epigenesis, Genetic
  • Humans
  • Lymphoma, Non-Hodgkin* / diagnosis
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Lymphoma, Non-Hodgkin* / genetics
  • Mutation
  • Neoplasm Recurrence, Local* / drug therapy
  • Neoplasm Recurrence, Local* / genetics

Substances

  • CREB-Binding Protein
  • CREBBP protein, human
  • E1A-Associated p300 Protein
  • EP300 protein, human
  • mocetinostat